Keratoconus is an eye condition that involves progressive thinning and bulging of the cornea. Keratoconus can significantly decrease vision, making it difficult for individuals to perform daily tasks. As the condition progresses, traditional glasses may become ineffective, and patients may require contact lenses or more advanced interventions. An effective and proven treatment for keratoconus is corneal crosslinking (CXL), a minimally invasive procedure that strengthens the corneal tissue. During CXL, the cornea is treated with riboflavin drops and then exposed to ultraviolet (UV) light. This process crosslinks collagen fibers in the cornea, thereby strengthening the cornea and delaying the progression of keratoconus. CXL has shown promising results in stabilizing the cornea and reducing the need for more invasive surgical options such as corneal transplants.
